<?xml version='1.0' encoding='utf-8'?>
<document id="29649743"><sentence text="Recent advances in trimethoxyphenyl (TMP) based tubulin inhibitors targeting the colchicine binding site."><entity charOffset="19-35" id="DDI-PubMed.29649743.s1.e0" text="trimethoxyphenyl" /><entity charOffset="37-40" id="DDI-PubMed.29649743.s1.e1" text="TMP" /><entity charOffset="81-91" id="DDI-PubMed.29649743.s1.e2" text="colchicine" /><pair ddi="false" e1="DDI-PubMed.29649743.s1.e0" e2="DDI-PubMed.29649743.s1.e0" /><pair ddi="false" e1="DDI-PubMed.29649743.s1.e0" e2="DDI-PubMed.29649743.s1.e1" /><pair ddi="false" e1="DDI-PubMed.29649743.s1.e0" e2="DDI-PubMed.29649743.s1.e2" /><pair ddi="false" e1="DDI-PubMed.29649743.s1.e1" e2="DDI-PubMed.29649743.s1.e1" /><pair ddi="false" e1="DDI-PubMed.29649743.s1.e1" e2="DDI-PubMed.29649743.s1.e2" /></sentence><sentence text="Microtubules (composed of α- and β-tubulin heterodimers) play a pivotal role in mitosis and cell division, and are regarded as an excellent target for chemotherapeutic agents to treat cancer" /><sentence text=" There are four unique binding sites in tubulin to which taxanes, vinca alkaloids, laulimalide and colchicine bind respectively"><entity charOffset="57-64" id="DDI-PubMed.29649743.s3.e0" text="taxanes" /><entity charOffset="72-81" id="DDI-PubMed.29649743.s3.e1" text="alkaloids" /><entity charOffset="83-94" id="DDI-PubMed.29649743.s3.e2" text="laulimalide" /><entity charOffset="99-109" id="DDI-PubMed.29649743.s3.e3" text="colchicine" /><pair ddi="false" e1="DDI-PubMed.29649743.s3.e0" e2="DDI-PubMed.29649743.s3.e0" /><pair ddi="false" e1="DDI-PubMed.29649743.s3.e0" e2="DDI-PubMed.29649743.s3.e1" /><pair ddi="false" e1="DDI-PubMed.29649743.s3.e0" e2="DDI-PubMed.29649743.s3.e2" /><pair ddi="false" e1="DDI-PubMed.29649743.s3.e0" e2="DDI-PubMed.29649743.s3.e3" /><pair ddi="false" e1="DDI-PubMed.29649743.s3.e1" e2="DDI-PubMed.29649743.s3.e1" /><pair ddi="false" e1="DDI-PubMed.29649743.s3.e1" e2="DDI-PubMed.29649743.s3.e2" /><pair ddi="false" e1="DDI-PubMed.29649743.s3.e1" e2="DDI-PubMed.29649743.s3.e3" /><pair ddi="false" e1="DDI-PubMed.29649743.s3.e2" e2="DDI-PubMed.29649743.s3.e2" /><pair ddi="false" e1="DDI-PubMed.29649743.s3.e2" e2="DDI-PubMed.29649743.s3.e3" /></sentence><sentence text=" While several tubulin inhibitors that bind to the taxane or vinca alkaloid binding sites have been approved by FDA, currently there are no FDA approved tubulin inhibitors targeting the colchicine binding site"><entity charOffset="51-57" id="DDI-PubMed.29649743.s4.e0" text="taxane" /><entity charOffset="67-75" id="DDI-PubMed.29649743.s4.e1" text="alkaloid" /><entity charOffset="186-196" id="DDI-PubMed.29649743.s4.e2" text="colchicine" /><pair ddi="false" e1="DDI-PubMed.29649743.s4.e0" e2="DDI-PubMed.29649743.s4.e0" /><pair ddi="false" e1="DDI-PubMed.29649743.s4.e0" e2="DDI-PubMed.29649743.s4.e1" /><pair ddi="false" e1="DDI-PubMed.29649743.s4.e0" e2="DDI-PubMed.29649743.s4.e2" /><pair ddi="false" e1="DDI-PubMed.29649743.s4.e1" e2="DDI-PubMed.29649743.s4.e1" /><pair ddi="false" e1="DDI-PubMed.29649743.s4.e1" e2="DDI-PubMed.29649743.s4.e2" /></sentence><sentence text=" Tubulin inhibitors that bind to the colchicine binding site have therapeutic advantages over taxanes and vinca alkaloids, for example, they can be administered orally, have less drug-drug interaction potential, and are less prone to develop multi-drug resistance"><entity charOffset="37-47" id="DDI-PubMed.29649743.s5.e0" text="colchicine" /><entity charOffset="94-101" id="DDI-PubMed.29649743.s5.e1" text="taxanes" /><entity charOffset="112-121" id="DDI-PubMed.29649743.s5.e2" text="alkaloids" /><pair ddi="false" e1="DDI-PubMed.29649743.s5.e0" e2="DDI-PubMed.29649743.s5.e0" /><pair ddi="false" e1="DDI-PubMed.29649743.s5.e0" e2="DDI-PubMed.29649743.s5.e1" /><pair ddi="false" e1="DDI-PubMed.29649743.s5.e0" e2="DDI-PubMed.29649743.s5.e2" /><pair ddi="false" e1="DDI-PubMed.29649743.s5.e1" e2="DDI-PubMed.29649743.s5.e1" /><pair ddi="false" e1="DDI-PubMed.29649743.s5.e1" e2="DDI-PubMed.29649743.s5.e2" /></sentence><sentence text=" Typically, tubulin inhibitors that bind to the colchicine binding site bear the trimethoxyphenyl (TMP) moiety which is essential for interaction with tubulin"><entity charOffset="48-58" id="DDI-PubMed.29649743.s6.e0" text="colchicine" /><entity charOffset="81-97" id="DDI-PubMed.29649743.s6.e1" text="trimethoxyphenyl" /><entity charOffset="99-102" id="DDI-PubMed.29649743.s6.e2" text="TMP" /><pair ddi="false" e1="DDI-PubMed.29649743.s6.e0" e2="DDI-PubMed.29649743.s6.e0" /><pair ddi="false" e1="DDI-PubMed.29649743.s6.e0" e2="DDI-PubMed.29649743.s6.e1" /><pair ddi="false" e1="DDI-PubMed.29649743.s6.e0" e2="DDI-PubMed.29649743.s6.e2" /><pair ddi="false" e1="DDI-PubMed.29649743.s6.e1" e2="DDI-PubMed.29649743.s6.e1" /><pair ddi="false" e1="DDI-PubMed.29649743.s6.e1" e2="DDI-PubMed.29649743.s6.e2" /></sentence><sentence text=" Over the last decade, a variety of molecules bearing the TMP moiety have been designed and synthesized as tubulin inhibitors for cancer treatment"><entity charOffset="58-61" id="DDI-PubMed.29649743.s7.e0" text="TMP" /></sentence><sentence text=" In this review, we focus on the TMP analogs that are designed based on CA-4, indole, chalcone, colchicine and natural product scaffolds which are known to interact with the colchicine binding site in tubulin"><entity charOffset="33-36" id="DDI-PubMed.29649743.s8.e0" text="TMP" /><entity charOffset="72-76" id="DDI-PubMed.29649743.s8.e1" text="CA-4" /><entity charOffset="78-84" id="DDI-PubMed.29649743.s8.e2" text="indole" /><entity charOffset="86-94" id="DDI-PubMed.29649743.s8.e3" text="chalcone" /><entity charOffset="96-106" id="DDI-PubMed.29649743.s8.e4" text="colchicine" /><entity charOffset="174-184" id="DDI-PubMed.29649743.s8.e5" text="colchicine" /><pair ddi="false" e1="DDI-PubMed.29649743.s8.e0" e2="DDI-PubMed.29649743.s8.e0" /><pair ddi="false" e1="DDI-PubMed.29649743.s8.e0" e2="DDI-PubMed.29649743.s8.e1" /><pair ddi="false" e1="DDI-PubMed.29649743.s8.e0" e2="DDI-PubMed.29649743.s8.e2" /><pair ddi="false" e1="DDI-PubMed.29649743.s8.e0" e2="DDI-PubMed.29649743.s8.e3" /><pair ddi="false" e1="DDI-PubMed.29649743.s8.e0" e2="DDI-PubMed.29649743.s8.e4" /><pair ddi="false" e1="DDI-PubMed.29649743.s8.e0" e2="DDI-PubMed.29649743.s8.e5" /><pair ddi="false" e1="DDI-PubMed.29649743.s8.e1" e2="DDI-PubMed.29649743.s8.e1" /><pair ddi="false" e1="DDI-PubMed.29649743.s8.e1" e2="DDI-PubMed.29649743.s8.e2" /><pair ddi="false" e1="DDI-PubMed.29649743.s8.e1" e2="DDI-PubMed.29649743.s8.e3" /><pair ddi="false" e1="DDI-PubMed.29649743.s8.e1" e2="DDI-PubMed.29649743.s8.e4" /><pair ddi="false" e1="DDI-PubMed.29649743.s8.e1" e2="DDI-PubMed.29649743.s8.e5" /><pair ddi="false" e1="DDI-PubMed.29649743.s8.e2" e2="DDI-PubMed.29649743.s8.e2" /><pair ddi="false" e1="DDI-PubMed.29649743.s8.e2" e2="DDI-PubMed.29649743.s8.e3" /><pair ddi="false" e1="DDI-PubMed.29649743.s8.e2" e2="DDI-PubMed.29649743.s8.e4" /><pair ddi="false" e1="DDI-PubMed.29649743.s8.e2" e2="DDI-PubMed.29649743.s8.e5" /><pair ddi="false" e1="DDI-PubMed.29649743.s8.e3" e2="DDI-PubMed.29649743.s8.e3" /><pair ddi="false" e1="DDI-PubMed.29649743.s8.e3" e2="DDI-PubMed.29649743.s8.e4" /><pair ddi="false" e1="DDI-PubMed.29649743.s8.e3" e2="DDI-PubMed.29649743.s8.e5" /><pair ddi="false" e1="DDI-PubMed.29649743.s8.e4" e2="DDI-PubMed.29649743.s8.e4" /><pair ddi="false" e1="DDI-PubMed.29649743.s8.e4" e2="DDI-PubMed.29649743.s8.e5" /></sentence><sentence text=" The challenges and future direction of the TMP based tubulin inhibitors are also discussed in detail"><entity charOffset="44-47" id="DDI-PubMed.29649743.s9.e0" text="TMP" /></sentence><sentence text="" /></document>